Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mod GRF 1-29

Sermorelin, Growth Hormone Releasing Hormone (1-29), hGRF(1-29)NH2

Quick Stats
Studies 227
Trials 47
Score 3
1989 pubmed

Repeated GH-releasing hormone administration unravels different GH secretory patterns in normal adults and children.

Ghigo. E E; Goffi. S S; Mazza. E E; Arvat. E E; Procopio. M M; Bellone. J J; Müller. E E EE; Camanni. F F

Key Findings

  • Adults show a marked decline in GH response to a second GHRH dose given 120 minutes after the first.
  • Children do not exhibit a significant drop in GH response to a second GHRH dose.
  • Pyridostigmine, a cholinergic enhancer, fails to increase GH response to the second GHRH dose in children.

Practical Outcomes

  • For biohackers using GRF‑1‑29, spacing doses more than two hours apart may be important to avoid reduced GH release in adults. Repeated dosing in a short window could blunt effectiveness. Adding cholinergic agents like pyridostigmine is unlikely to rescue the response, so they probably won’t improve results.

Summary

In healthy adults, giving a second dose of GHRH about two hours after the first leads to a much smaller growth hormone (GH) spike, while kids don’t show this drop. Adding a cholinesterase blocker (pyridostigmine) that helped adults doesn’t boost the GH response in children either.

Abstract

In normal adults, repeated GHRH administration leads to progressively decreasing somatotrope responses. To verify whether this GH secretory pattern also connotes normal growing children, we have studied the effects of two consecutive (every 120 min) 1 microgram/kg iv GHRH boluses on GH release in normal adults (N = 7, age 23.2-30.6 years) children (N = 6, age 10.4-13.2 years). In the adults, the GH response to the second GHRH bolus (peak, mean +/- SEM; 2.9 +/- 0.8 micrograms/l) was lower (P less than 0.02) than that to the first bolus (15.9 +/- 2.4 micrograms/l). Conversely, in children the GH response to the second GHRH bolus (25.6 +/- 6.3 micrograms/l) overrode the first one (13.6 +/- 6.5 micrograms/l), but this difference did not attain statistical significance. In adults cholinergic enhancement by pyridostigmine, a cholinesterase inhibitor, was previously shown to re-instate, even to potentiate somatotrope responsiveness to consecutive GHRH boluses. Thus, in 5 children GH response to repeated GHRH boluses was retested administering pyridostigmine (60 mg orally) 30 min before the second GHRH bolus. In these subjects, pyridostigmine failed significantly to potentiate the GH responsiveness to the second GHRH bolus (30.3 +/- 4.6 vs 25.0 +/- 7.6 micrograms/l). These data indicate that differently from in adults, in children repeated GHRH administration does not reduce somatotrope responsiveness and that cholinergic enhancement fails to potentiate GH responsiveness to the second GHRH bolus.

Study Information

Provider

pubmed

Year

1989

DOI

10.1530/acta.0.1200598